Among immunotherapies targeting TAM repolarization in CRC, phase I trials have been completed for pexidartinib (CSF-1R antagonist) with durvalumab and CCR5 inhibitors as monotherapy, as well as phase I trials and recruitment of CT-0508 (chimeric antigen receptor macrophages) as monotherapy (reviewed in [177]). This evidence concerns the gene CCR5 and colorectal carcinoma.